AU2018361249B2 - Aminoimidazopyridazines as kinase inhibitors - Google Patents

Aminoimidazopyridazines as kinase inhibitors Download PDF

Info

Publication number
AU2018361249B2
AU2018361249B2 AU2018361249A AU2018361249A AU2018361249B2 AU 2018361249 B2 AU2018361249 B2 AU 2018361249B2 AU 2018361249 A AU2018361249 A AU 2018361249A AU 2018361249 A AU2018361249 A AU 2018361249A AU 2018361249 B2 AU2018361249 B2 AU 2018361249B2
Authority
AU
Australia
Prior art keywords
pyridazin
methyl
acetamidoimidazo
carboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018361249A
Other languages
English (en)
Other versions
AU2018361249A1 (en
Inventor
Carolyn Diane Dzierba
Jason M. Guernon
Amy C. HART
Guanglin Luo
John E. Macor
Michael E. Mertzman
William J. Pitts
Jianliang Shi
Steven H. Spergel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2018361249A1 publication Critical patent/AU2018361249A1/en
Application granted granted Critical
Publication of AU2018361249B2 publication Critical patent/AU2018361249B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018361249A 2017-10-30 2018-10-29 Aminoimidazopyridazines as kinase inhibitors Ceased AU2018361249B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762578607P 2017-10-30 2017-10-30
US62/578,607 2017-10-30
US201862626853P 2018-02-06 2018-02-06
US62/626,853 2018-02-06
PCT/US2018/057968 WO2019089442A1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridines as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2018361249A1 AU2018361249A1 (en) 2020-06-11
AU2018361249B2 true AU2018361249B2 (en) 2022-08-25

Family

ID=64332173

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018361249A Ceased AU2018361249B2 (en) 2017-10-30 2018-10-29 Aminoimidazopyridazines as kinase inhibitors

Country Status (23)

Country Link
US (1) US11440913B2 (https=)
EP (1) EP3704118B1 (https=)
JP (1) JP7228586B2 (https=)
KR (1) KR102662197B1 (https=)
CN (1) CN111566103B (https=)
AU (1) AU2018361249B2 (https=)
BR (1) BR112020007557A2 (https=)
CA (1) CA3080402A1 (https=)
CY (1) CY1124984T1 (https=)
DK (1) DK3704118T3 (https=)
ES (1) ES2905948T3 (https=)
HR (1) HRP20220297T1 (https=)
HU (1) HUE058292T2 (https=)
IL (1) IL274207B2 (https=)
LT (1) LT3704118T (https=)
MX (1) MX2020003706A (https=)
PL (1) PL3704118T3 (https=)
PT (1) PT3704118T (https=)
RS (1) RS62974B1 (https=)
SG (1) SG11202003824PA (https=)
SI (1) SI3704118T1 (https=)
SM (1) SMT202200087T1 (https=)
WO (1) WO2019089442A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580220B1 (en) 2017-02-13 2021-11-17 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors
SG11202007035YA (en) 2018-01-26 2020-08-28 Bristol Myers Squibb Co Aminopyrrolotriazines as kinase inhibitors
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2021067654A1 (en) * 2019-10-03 2021-04-08 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
WO2021168521A1 (en) * 2020-02-27 2021-09-02 Anaxis Pharma Pty Ltd Inhibitors of necroptosis
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AU2021362678A1 (en) * 2020-10-13 2023-05-04 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN120530112A (zh) * 2022-12-30 2025-08-22 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163489A1 (en) * 2007-12-19 2009-06-25 Shon Booker Inhibitors of PI3 kinase
US20100075965A1 (en) * 2006-02-14 2010-03-25 Novartis Ag Pi3 kinase inhibitors and methods of their use
WO2018148626A1 (en) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750517A1 (en) * 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
HK1219737A1 (zh) 2013-06-10 2017-04-13 Bayer Pharma Aktiengesellschaft 用於治疗癌症的新化合物
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
SG11202007035YA (en) 2018-01-26 2020-08-28 Bristol Myers Squibb Co Aminopyrrolotriazines as kinase inhibitors
EP3849968B1 (en) 2018-09-13 2022-12-21 Bristol-Myers Squibb Company 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
EP3877371A4 (en) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075965A1 (en) * 2006-02-14 2010-03-25 Novartis Ag Pi3 kinase inhibitors and methods of their use
US20090163489A1 (en) * 2007-12-19 2009-06-25 Shon Booker Inhibitors of PI3 kinase
WO2018148626A1 (en) * 2017-02-13 2018-08-16 Bristol-Myers Squibb Company Aminotriazolopyridines as kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 12, 2013, pages 1238 - 1243. *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 4, 2017, pages 1247 - 1261 *

Also Published As

Publication number Publication date
US20200277296A1 (en) 2020-09-03
ES2905948T3 (es) 2022-04-12
HRP20220297T1 (hr) 2022-05-13
HUE058292T2 (hu) 2022-07-28
IL274207B (en) 2022-12-01
CN111566103A (zh) 2020-08-21
AU2018361249A1 (en) 2020-06-11
MX2020003706A (es) 2020-07-22
WO2019089442A8 (en) 2019-06-27
SG11202003824PA (en) 2020-05-28
CA3080402A1 (en) 2019-05-09
KR20200078591A (ko) 2020-07-01
LT3704118T (lt) 2022-02-25
RS62974B1 (sr) 2022-03-31
WO2019089442A1 (en) 2019-05-09
EP3704118A1 (en) 2020-09-09
PL3704118T3 (pl) 2022-04-04
PT3704118T (pt) 2022-02-14
BR112020007557A2 (pt) 2020-09-24
CY1124984T1 (el) 2023-01-05
US11440913B2 (en) 2022-09-13
JP7228586B2 (ja) 2023-02-24
JP2021501179A (ja) 2021-01-14
SI3704118T1 (sl) 2022-04-29
SMT202200087T1 (it) 2022-03-21
DK3704118T3 (da) 2022-03-14
IL274207A (en) 2020-06-30
EP3704118B1 (en) 2022-01-12
IL274207B2 (en) 2023-04-01
CN111566103B (zh) 2023-06-23
KR102662197B1 (ko) 2024-04-29

Similar Documents

Publication Publication Date Title
AU2018361249B2 (en) Aminoimidazopyridazines as kinase inhibitors
US12157733B2 (en) Aminotriazolopyridines as kinase inhibitors
CN104159896B (zh) 用作激酶抑制剂的杂环取代的吡啶基化合物
CN104254533B (zh) 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
EP3743430B1 (en) Aminopyrrolotriazines as kinase inhibitors
EP3849968B1 (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
EP3849969B1 (en) Indazole carboxamides as kinase inhibitors
EA042124B1 (ru) Аминоимидазопиридазины в качестве ингибиторов киназ

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired